Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch ...